Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination

MAJOR ARTICLE Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination Wellington Sun, 1 Ananda Nisalak, 3 Montip Gettayacamin, 4 Kenneth H. Eckels, 2 J. Robert Putnak, 1 David W. Vaughn, 1,a Bruce L. Innis, 1,a Stephen J. Thomas, 1 and Timothy P. Endy 3,a Departments of 1 Virus Diseases and 2 Biologics Research, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland; Departments of 3 Virology and 4 Veterinary Medicine, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand Rhesus monkeys develop viremia after dengue virus (DENV) inoculation and have been used as an animal model to study DENV infection and DENV vaccine candidates. We evaluated, in this model, the protective efficacy of a live attenuated tetravalent DENV vaccine (TDV) candidate against parenteral challenge with parental near-wild-type DENV strains. Twenty monkeys were vaccinated with TDV at 0 and 1 month, and 20 unvaccinated monkeys served as controls. Vaccinated animals and their controls were inoculated with 10 3 10 4 pfu of challenge virus 4.5 months after the second vaccination. Primary vaccination resulted in 95%, 100%, 70%, and 15% seroconversion to DENV serotypes 1, 2, 3, and 4 (DENV-1, -2, -3, and -4), respectively. After the second vaccination, the seropositivity rates were 100%, 100%, 90%, and 70%, respectively. Vaccination with TDV resulted in complete protection against viremia from DENV-2 challenge and in 80%, 80%, and 50% protection against challenge with DENV-1, -3, and -4, respectively. Our results suggest that the TDV can elicit protective immunity against all 4 DENV serotypes. Interference among the 4 vaccine viruses may have resulted in decreased antibody responses to DENV-3 and -4, which would require reformulation or dose optimization to minimize this interference during testing of the vaccine in humans. Dengue virus (DENV) is a mosquitoborne flavivirus responsible for 50 100 million infections per year [1]. Dengue fever (DF) and dengue hemorrhagic fever (DHF) Received 30 September 2005; accepted 17 November 2005; electronically published 9 May 2006. Potential conflicts of interest: Partially on the basis of this study, some authors were named inventors on an awarded patent (6638514), titled Multivalent dengue vaccine, filed 24 March 2000 and awarded 28 October 2003. Financial support: US Army Medical Research and Materiel Command. The views expressed herein are those of the authors and do not necessarily represent those of the Department of the Army or Department of Defense. a Present affiliations: Military Infectious Diseases Research Program, Medical Research and Materiel Command, Fort Detrick (D.W.V.), and Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland (T.P.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (B.L.I.). Reprints or correspondence: Dr. Wellington Sun, Dept. of Virus Diseases, Div. of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910-7500 (wellinton.sun@ us.army.mil). The Journal of Infectious Diseases 2006; 193:1658 65 This article is in the public domain, and no copyright is claimed. 0022-1899/2006/19312-0008 are serious global health problems with significant economic impact [2]. There are 4 DENV serotypes, each of which can cause DF and DHF. Primary infection is often subclinical or manifests as an acute, self-limited febrile illness and results in homologous long-term immunity to the infecting serotype [3]. A secondary infection by a heterologous serotype is more frequently associated with DHF or dengue shock syndrome [4, 5]. The pathogenesis of DHF may be a result of sequential DENV infections, in which preexisting immunity from a previous DENV infection results in enhanced clinical severity [6 10]. A tetravalent DENV vaccine (TDV) that induces immunity against all 4 serotypes is the best hope for controlling this disease. Obstacles to the development of a TDV exist. One such obstacle is the lack of an appropriate animal model. The closest animal model of DENV infection in humans is the rhesus monkey, Macaca mulatta [11, 12]. Although DENV infection of rhesus monkeys does not cause overt 1658 JID 2006:193 (15 June) Sun et al.

disease, the virus causes viremia, production of neutralizing antibody, and changes in hematological parameters indicating viral replication [11, 13]. Similar to humans, exposure of rhesus monkeys to one serotype of DENV induces solid immunity to that serotype but not to the others [12, 14]. Reduction of viremia in these animals after virus challenge has been used as an indicator of attenuation of the virus in humans [15]. We used this model to describe the protection afforded by a live attenuated TDV against subsequent challenge with near-wild-type DENV several months later. Such protection in rhesus monkeys may suggest that similar protection could be achieved in vaccinated humans. MATERIALS AND METHODS Rhesus monkeys. Young adult rhesus monkeys of Indian origin, bred at the veterinary facility of the US Army Medical Component, Armed Forces Research Institute of the Medical Sciences (USAMC-AFRIMS), Bangkok, Thailand, were used for this study. The USAMC-AFRIMS Animal Care and Use Program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC). Monkeys were housed and handled in accordance with institutional guidelines. All monkeys were skin-test negative for tuberculosis and seronegative for cercopithecine herpesvirus 1 (B virus), simian retrovirus, simian immunodeficiency virus, and simian T cell leukemia virus type 1, by standard commercial assays. Before entry into the study, all monkeys tested negative for DENV serotypes 1, 2, 3, and 4 (DENV-1, -2, -3, -4) and for Japanese encephalitis virus antibody by hemagglutination-inhibition and neutralizing-antibody assay [16, 17]. The monkeys were inbred locally and therefore not screened for yellow fever virus antibody. Research was in compliance with the Animal Welfare Act and with principles of the National Research Council [18]. The protocol was approved by the institute s Animal Care and Use Committee and by the Animal Use Review Division of the US Army Medical Research and Material Command. This study was performed in 1999. Vaccine viruses. The 4 DENV serotype vaccine strains were each derived from a human clinical isolate. Viral attenuation by serial passages in primary dog kidney cell cultures and then fetal rhesus monkey lung cells was performed as described elsewhere [19]. Each vaccine was produced under Good Manufacturing Practice regulations as a single lot; the same lots have been used in clinical trials [20]. The vaccine virus strains were designated DENV-1 45AZ5 PDK20, DENV-2 S16803 PDK50, DENV-3 CH53489 PDK20, and DENV-4 341750 PDK20. Each lyophilized monovalent vaccine was reconstituted with sterile water and administered in a volume of 0.5 ml. The doses of DENV-1, -2, -3, and -4 were 10 6,10 6,10 5,and10 5 pfu/ml, respectively. The TDV dose was prepared by mixing 0.25 ml of each reconstituted monovalent component and was administered in a total volume of 1 ml 0.5 ml administered subcutaneously in each upper arm. The dose of the TDV was 6 6 1.1 10 2.8 10 pfu/ml. Challenge viruses. The 4 challenge virus strains were DENV- 1 West Pac 74, DENV-2 S16803 PDK10, DENV-3 CH53489, and DENV-4 341750. DENV-1, -3, and -4 are parent viruses of the vaccines. The DENV-1, -2, and -4 strains have previously consistently produced viremia in rhesus monkeys: 4 of 4 monkeys (mean, 6.8 days of viremia), 4 of 4 monkeys (mean, 5 days), and 3 of 3 monkeys (mean, 4.7 days), for the DENV-1, -2, and -4 strains, respectively [19]. The present study is the first in which the DENV-3 CH53489 strain has been used in a rhesus monkey challenge. Vaccination and challenge schedule. Monkeys were randomly assigned to 1 of 3 groups: validation, vaccine, and control, consisting of 12, 20, and 8 monkeys, respectively. The validation group had 2 purposes: (1) to ensure that the challenge viruses consistently induced viremia and (2) to compare the 2 viremia detection methods. The 12 monkeys in the validation group were divided into 4 subgroups of 3 monkeys each. Each subgroup received 1 of the 4 challenge viruses. After successful validation of each challenge virus, the 20 monkeys in the vaccine group were administered TDV on days 0 and 32, and the 8 controls were inoculated with saline placebo on the same study days. The study veterinarian and caretakers were blinded to the test article assignments. At 4.5 months after the second vaccination, the 20 vaccinated monkeys were randomly divided into 4 subgroups of 5 monkeys each, and each subgroup was challenged with 1 of the 4 challenge viruses. Concurrently, the 8 monkeys in the control group, all of which were flavivirus naive, were divided into 4 subgroups of 2 monkeys each, and each subgroup was randomly assigned and challenged with 1 serotype of the challenge viruses. All challenges were administered subcutaneously in a shaved medial upper arm. Blood collection. Approximately 5.0 ml of blood was collected from each monkey 6 weeks before the first inoculation, to ascertain flavivirus antibody status. For the validation group, 2.0 ml of blood was collected on study day 0 (day of challenge) and then on study days 1 12 and 21. For the vaccine and control groups, 2.0 ml of blood was collected on study days 0 (before inoculation), 21, 167 (4.5 months after dose 2, on the day of challenge), then daily for 12 days (study days 168 179), and then finally on study day 194 (4 weeks after challenge). All blood specimens were coded so that the laboratory studies were performed in blinded fashion. Virus isolation and quantitation. End-point titrations on LLC/MK 2 cell monolayers were performed on all residual vaccine and challenge inocula, for verification of titers. Plasma collected after challenge from the validation-group monkeys was DENV Vaccination in Nonhuman Primates JID 2006:193 (15 June) 1659

Table 1. Reciprocal 50% plaque-reduction neutralization titers and viremia after challenge in flavivirus-naive rhesus monkeys. Challenge virus, group, monkey Dose of challenge virus, pfu Postchallenge viremia, study days (total duration, days) 1 month postchallenge titer Mosquito inoculation Nested PCR DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 Validation DA584 1.5 10 3 Days 5 9 (5) Days 4 8 (5) 1471 308 32 18 DA611 1.5 10 3 Days 4 10 (7) Days 4 9 (6) 1281 252 33 12 DA632 1.5 10 3 Days 3 8 (6) Days 3 8 (6) 2560 139 318!10 Control DA397 5.0 10 4 ND Days 3 8 (6) 2560 405 90!10 DA520 5.0 10 4 ND Days 4 7 (4) 1873 46 52!10 GMT 1874 182 69 3 DENV 2 Validation DA638 2.5 10 4 Days 6 10 (5) Days 5 10 (6) 173 12560!10!10 DA659 2.5 10 4 Days 6 9 (4) Days 4 9 (6) 16 12560!10!10 DA662 2.5 10 4 Days 6 11 (6) Days 3 12 (10) 74 1632 19!10 Control DA571 2.0 10 4 ND Days 3 9 (7) 105 1197 48 12 DA618 2.0 10 4 ND Days 4 11 (8) 34 1459 55 15 GMT 59 1796 9 3 DENV-3 Validation DA616 2.5 10 3 Day 7 (1) Days 2, 5 8 (5) 87 43 1099!10 DA676 2.5 10 3 Days 7 9 (3) Days 4 8 (5) 17 62 627!10 DA699 2.5 10 3 Day 7 (1) Days 2, 4, 6 7 (4) 18 85 1320!10 Control DA642 5.0 10 2 ND Days 2 7 (6) 96 93 12560!10 DA630 2.5 10 3 ND Days 2 8 (7) 41 136 1570!10 GMT 40 78 1296 1 DENV-4 Validation DA684 4.5 10 3 Days 7 11 (5) Days 2, 4 12 (10)!10 173!10 376 DA685 4.5 10 3 Day 8 (1) Days 5, 7 8 (3)!10 42!10 376 DA694 4.5 10 3 Days 5 11 (7) Days 4 9, 12 (7) 348 150 30 892 Control DA678 5.0 10 4 ND Days 6 9 (4) 94 34 10 961 DA681 5.0 10 4 ND None!10!10!10 40 GMT 8 33 3 344 NOTE. Prechallenge titers of all viruses were!10. Titers of the serotype homologous to the challenge serotype are highlighted in bold. DENV, dengue virus; GMT, geometric mean titer; ND, not done; PCR, polymerase chain reaction. used to compare the sensitivity of 2 viral isolation methods: intrathoracic inoculation into Toxorhynchites splendens [21] mosquitoes and a nested reverse-transcription polymerase chain reaction (RT-PCR) assay, described elsewhere [22, 23]. Briefly, for each plasma specimen, 20 T. splendens mosquitoes were each injected with 0.17 ml of plasma, using a microcapillary pipette. Inoculated mosquitoes were reared at room temperature for 2 weeks and then killed, and the heads were tested for DENV by a DENV-specific immunofluoresence antibody (IFA) method. The bodies of mosquitoes testing positive for DENV by the IFA method were then ground up, and viral isolation on Vero cells was completed as described elsewhere [24, 25]. The nestedprimer RT-PCR used was a DENV serotype specific virus RNA detection assay, performed using a modified Lanciotti method [23]. Oligonucleotide primers used to amplify and type DENV were D1 (5 -TCA ATA TGC TGA AAC GCG CGA GAA ACC G-3 ), D2 (5 -TTG CAC CAA CAG TCA ATG TCT TCA GGT TC-3 ), TS1 (5 -CGT CTC AGT GAT CCG GGG G-3 ), TS2 (5-1660 JID 2006:193 (15 June) Sun et al.

Table 2. Reciprocal 50% plaque-reduction neutralization titers in flavivirus-naive rhesus monkeys after 2 doses of tetravalent dengue virus (DENV) vaccine at 0 and 1 month. 21 days after dose 1 4.5 months after dose 2 Monkey DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DA552 58 522!10!10 92 1166 48!10 DA557 317 147 512!10 456 1042 234 36 DA574 87 257 20 14 97 76 93!10 DA575 14 86 40!10 20 260 27!10 DA586 1640 12560 1640!10 1041 1381 298 13 DA592 289 330 40!10 12560 1200 12560 499 DA599 1640 480 1640!10 710 333 1012 20 DA614 94 186 16 21 522 411 287 1148 DA620 134 52!10!10 37 121!10!10 DA625 182 594 12560!10 365 274 99!10 DA644 117 177!10!10 1093 12560 1967 150 DA646 205 66 61!10 886 656 145 766 DA649!10 74 19!10 1072 294 132 28 DA650 12560 1216 315!10 403 559 119 20 DA651 44 63!10!10 86 192 13 48 DA658 179 451 531!10 115 681 278 10 DA661 107 243!10!10 176 148 12!10 DA664 110 226 41 12 253 825 1843 70 DA672 248 126 146!10 205 258!10 10 DA688 101 62!10!10 12560 12560 80 37 Seropositivity rate, % 95 100 70 15 100 100 90 70 GMT 125 216 30 2 317 485 121 28 NOTE. Prechallenge titers of all viruses were!10. GMT, geometric mean titer. CGC CAC AAG GGC CAT GAA CAG-3 ), TS3 (5 -TAA CAT CAT CAT GAG ACA GAG C-3 ), and TS4 (5 -CTC TGT TGT CTT AAA CAA GAG A-3 ). The nested RT-PCR was performed on serum to measure viremia after challenge. Plaque-reduction neutralization test. DENV-specific neutralizing antibody titers were determined using previously described methods [16]. Briefly, a monolayer of LLC/MK 2 cells was inoculated with 50 pfu of reference virus. The reference virus strains were DENV-1 16007, DENV-2 16681, DENV-3 16562, and DENV-4 1036. All samples were were coded, heat inactivated, and assayed in a blinded fashion in duplicate at 4- fold serial dilutions of 1:10, 1:40, 1:160, 1:640, and 1:2560. The 50% plaque-reduction neutralization titer (PRNT 50 ) was calculated by use of a log probit regression method and reported as a reciprocal titer. A titer of 1:10 was considered to be positive. A value of 1 was used for titers!1:10 in the calculation of geometric mean titer (GMT). Titers of 11:640 or 11:2560 indicate that no higher titration was performed; those values were used in GMT calculations. Statistical analysis. Days of viremia were compared using a 2-sample t test. Onset of viremia was compared using analysis of variance (ANOVA). Differences in seroconversion rates between groups were compared using the x 2 test. Differences in fold increases in antibody titers were compared using Mann- Whitney analysis. Statistical analysis was performed using SPSS software (version 10.0; SPSS). For all analyses, P.05 was considered to be significant. RESULTS Validation of challenge viruses: viremia and neutralizing antibody in unvaccinated monkeys after challenge. All 4 challenge viruses produced viremia in all validation-group monkeys, as assessed by both mosquito inoculation and nested RT-PCR methods. Table 1 shows that, in the validation group, more days of viremia were detected by the nested RT-PCR method than by mosquito inoculation, with means of 6.1 days and 4.3 days, respectively ( P p.05). The differences were especially marked with DENV-3 and -4. On the basis of these results, the nested RT-PCR was considered to be more sensitive and was used for determining viremia in the subsequent vaccine and control group experiments. Results from all 20 flavivirus-naive monkeys in the validation and control groups are shown together in table 1. Nineteen of these 20 monkeys that were given challenge developed viremia. Only 1 animal challenged with DENV-4, DA681, did not develop viremia and was not included in the analysis. The mean durations of viremia were 5.4, 7.4, 5.4, and 6.0 days for DENV- DENV Vaccination in Nonhuman Primates JID 2006:193 (15 June) 1661

Table 3. Reciprocal 50% plaque-reduction neutralization titers and viremia in rhesus monkeys that received the tetravalent dengue virus (DENV) vaccine. Challenge virus, monkey DENV-1 Postchallenge Prechallenge titer Dose of viremia, study (4.5 months after dose 2) 28 days postchallenge titer challenge days (total DENV-1 DENV-2 DENV-3 DENV-4 virus, pfu duration, days) DENV-1 DENV-2 DENV-3 DENV-4 DA552 92 1166 48!10 5.0 10 4 None 402 782 1288 22 DA557 456 1042 234 36 5.0 10 4 None 2278 12560 189 165 DA574 97 76 93!10 5.0 10 4 None 12560 2238 239 53 DA575 20 260 27!10 5.0 10 4 Days 5 6 (2) 1992 1500 656 145 DA586 1041 1381 298 13 5.0 10 4 None 1028 1633 293 13 DENV-2 DA592 12560 1200 12560 499 2.0 10 4 None 12560 1099 12560 957 DA599 710 333 1012 20 2.0 10 4 None 651 590 651 26 DA614 522 411 287 1148 2.0 10 4 None 253 320 114 2037 DA620 37 121!10!10 2.0 10 4 None 195 334 63 19 DA625 365 274 99!10 2.0 10 4 None 138 390 135 22 DENV-3 DA644 1093 12560 1967 150 5.0 10 2 None 1372 12560 12560 219 DA646 886 656 145 766 5.0 10 2 None 1074 2014 412 751 DA649 1072 294 132 28 5.0 10 2 None 989 711 136 32 DA650 403 559 119 20 5.0 10 2 Days 3 8 (6) 12560 1670 12560 247 DA651 86 192 13 48 5.0 10 2 None 1198 593 501 555 DENV-4 DA658 115 681 278 10 5.0 10 4 Day 6 (1) 12560 12560 12560 1188 DA661 176 148 12!10 5.0 10 4 Days 6 9 (4) 554 642 747 2423 DA664 253 825 1843 70 5.0 10 4 None 202 2063 1187 269 DA672 205 258!10 10 5.0 10 4 None 250 216 142 100 DA688 12560 12560 80 37 5.0 10 4 None 12560 2160 241 377 NOTE. Titers of the serotype homologous to the challenge serotype are highlighted in bold. 1, -2, -3, and 4, respectively. DENV-3 caused the earliest onset of viremia. The median days of onset of viremia were days 4, 4, 2, and 4.5, respectively. No significant differences were noted between serotypes in total days of viremia ( P 1.05, ANOVA). All monkeys in the validation and control groups seroconverted to the challenge viruses, including monkey DA681, which had no viremia detected after DENV-4 challenge. As expected for these flavivirus-naive monkeys, the challenge virus induced the highest antibody titer against the homologous serotype. GMTs were 3log10 for DENV-1, -2, and -3 and were 2log10 for DENV-4. GMTs against the homologous viruses were all at least 10-fold higher than those against heterologous viruses after challenge. Cross-reactive, heterotypic antibodies were elicited in all monkeys except DA681. In the flavivirus-naive monkeys, crossreactivity of neutralizing antibodies varied among serotype combinations. For example, recipients of DENV-1 had relatively high levels of cross-reactive DENV-2 antibody, with a DENV-1: DENV-2 GMT ratio of 10, and, reciprocally, recipients of DENV- 2 had a DENV-2:DENV-1 GMT ratio of 30. In contrast, DENV- 3 induced no cross-reactivity with DENV-4 at all, and, reciprocally, DENV-4 had little cross-reactivity with DENV-3. Notably, antibody cross-reactivity was not necessarily reciprocal. For example, monkeys challenged with DENV-2 developed very little cross-reactive antibody to DENV-4, with a DENV-2:DENV-4 GMT ratio of 599, but the DENV-4:DENV-2 GMT ratio was only 10. Neutralizing antibody response to tetravalent vaccinations. The antibody responses in the 20 monkeys vaccinated with TDV are shown in table 2. Seroconversion rates after a single dose of TDV were 95%, 100%, 70%, and 15% to DENV-1, -2, -3, and -4, respectively (table 2). Seropositivity rates 4.5 months after the second vaccination were 100%, 100%, 90%, and 70%, respectively. Thirteen (65%) of 20 monkeys developed neutralizing antibodies to all 4 serotypes after 2 vaccinations. Six (30%) of 20 monkeys developed trivalent responses, 2 lacked a response to DENV-3, and 6 lacked a response to DENV-4. Altogether, 19 (95%) of 20 monkeys developed a tri- or tetravalent neutralizing antibody response after a 2-dose vaccination schedule. On the basis of seroconversion rates and GMTs, the DENV-2 component appeared to be the most immunogenic, followed by DENV-1, -3, and -4, in descending order. 1662 JID 2006:193 (15 June) Sun et al.

Table 4. Viremia in rhesus monkeys after challenge. Challenge virus No. with viremia/total no. Mean viremia duration, days Validation and control groups Unvaccinated Vaccinated Vaccine group DENV-1 5/5 1/5 5.4 0.4 a DENV-2 5/5 0/5 7.4 0 a DENV-3 5/5 1/5 5.4 1.2 DENV-4 4/5 2/5 4.8 1.0 a NOTE. DENV, dengue virus. a Difference significant at P p.05 (Mann-Whitney). Viremia and antibody response in vaccinated monkeys after challenge. Table 3 shows each monkey s neutralizing antibody status in relation to viremia. The durations of viremia were significantly reduced in the vaccinated monkeys (table 4), except for those challenged with DENV-3 ( P p.07). All 5 vaccinated monkeys challenged with DENV-2 were completely protected, as is shown by an absence of DENV viremia. None of these 5 monkeys showed any significant ( 4-fold) increase in DENV- 2 antibody titer after challenge. Complete protection against DENV-1, -3, and -4 challenge was observed in 4 of 5, 4 of 5, and 3 of 5 vaccinated monkeys, respectively. Even in the vaccinated monkeys with breakthrough viremia, the durations were shorter than in the control monkeys. The lone exception was monkey DA650, whose duration of DENV-3 viremia was 6 days, compared with the controls mean duration of 5.4 days. All 16 vaccinated monkeys that were completely protected against challenge had measurable neutralizing antibodies to the homologous challenge serotype at the time of challenge. Three of 4 vaccinated monkeys that were incompletely protected had measurable antibody to the homologous challenge serotype. GMTs in the protected and unprotected monkeys were 165 and 19, respectively. One of 5 monkeys (DA575) challenged with DENV-1 developed viremia of 2 days duration. The prechallenge antibody titer in this monkey was 1:20, which was the lowest titer among the 5 monkeys. The single monkey (DA650) that developed viremia after DENV-3 challenge had a prechallenge antibody titer of 1: 119. Interestingly, another monkey (DA651) protected from challenge with DENV-3 had a prechallenge titer of 1:13. After DENV- 4 challenge, 2 of the 5 vaccinated monkeys (DA658 and DA661) developed viremia of 1 and 4 days duration, respectively. These 2 monkeys had titers of 1:10 and!1:10 at the time of challenge, respectively. Among the vaccinated animals, the highest boosts in postchallenge homologous antibody titers were seen in the 4 animals that developed viremia. The 5 completely protected monkeys in the DENV-2 challenge group had the lowest ratios of postchallenge to prechallenge DENV-2 antibody titer (1.0 2.8- fold), suggesting that there was little, if any, viral replication. The mean fold increase of postchallenge antibody titers in all vaccinated monkeys with breakthrough viremia, compared with that in all protected monkeys, was 120-fold versus 7-fold ( P!.006). DISCUSSION Overall, our 4 challenge viruses consistently produced viremia of 3 10 days duration in rhesus monkeys. One exception was a control-group monkey that did not develop viremia after DENV-4 challenge. However, this monkey did seroconvert to DENV-4, indicating that DENV-4 infection did occur. These challenge viruses have also induced reproducible viremia in cynomolgus monkeys [26]. Not surprisingly, each challenge virus induced almost a 1log 10 higher GMT than the vaccine viruses, which is consistent with our experience that the more attenuated vaccine viruses elicit lower levels of neutralizing antibodies. Our study provides evidence that the live attenuated TDV protected rhesus monkeys against DENV challenge. Eckels et al. previously showed that a single dose of each of the monovalent components of the TDV induced 100% seroconversion in rhesus monkeys [19]. In that study, the titers of vaccine virus were similar to, or 1log 10 lower than, those used in this study. In our study, the antibody responses to DENV-1 and -2 after a single dose of TDV were similar to those in rhesus monkeys that were administered the monovalent vaccine viruses. This was not the case with DENV-3 and -4, for which the seroconversion rates after a single dose of TDV were 14 (70%) of 20 and 3 (15%) of 20, much less than the 100% observed when these viruses were given alone. Similarly, the GMTs after 1 dose of TDV were highest for DENV-1 and -2 and lowest for DENV- 4. Thus, the DENV-1 and -2 components appeared to suffer no loss of immunogenicity when given as TDV, whereas DENV- 3 and -4 elicited lower antibody responses when given as TDV, suggesting viral interference. Possibly, the immunogenicity of TDV depends not only on the dose but also on the dose ratios among the individual components. Such dose-dependent interference has been observed with other live attenuated TDVs in cynomolgus and rhesus monkeys that were given the ChimeriVax-DENV TDV and the TDV containing chimeric and 3 -untranslated region deletion mutants [26, 27]. Sabin made similar observations, using volunteers; he observed that the simultaneous administration of equal doses of DENV-1 and -2 viruses resulted in suppression of or delay in the development of DENV-1 antibody [28]. When DENV-1 was administered DENV Vaccination in Nonhuman Primates JID 2006:193 (15 June) 1663

after DENV-2 at an interval of!6 weeks, no DENV-1 antibody developed. Apparent interference among TDV serotypes in humans was also observed with the Mahidol/Aventis vaccine, in which DENV-3 was immunodominant [29]. We anticipated that a second dose of TDV vaccination would be required to overcome interference. A second dose of TDV administered 32 days after the first dose appeared to have boosted seroconversion to DENV-3 and -4 in the monkeys. A parallel control group that does not receive a second vaccine would be needed to confirm this. Interestingly, when human subjects were given TDV by use of the same 0- and 1-month schedule, there were no additional seroconversions from the second vaccination [20]. This difference between rhesus monkeys and humans suggests that optimization of the vaccination schedule should be done in clinical trials. Like the monovalent DENV inoculations in Sabin s experiments, the TDV will likely require an interval longer than 1 month between vaccinations, to induce maximal antibody responses. Natural DENV infection results in protection against heterotypic DENV for 6 months but in decades-long protection against the homotypic DENV [28, 30]. DENV neutralizing antibody after natural infection is thought to be the marker of protective immunity. By inference, serotypic neutralizing antibodies are considered to be markers for vaccine-induced protection, which may be embodied as T cell and B cell memory. Previous studies showed that DENV infection produces a diversity of antibodies that are protective but also may include enhancing antibodies that mediate DHF [31 33]. There may be qualitative differences between antibodies from natural infections and those from TDV vaccination. Each single virus delivered in a tetravalent formulation might induce a panoply of homotypic and heterotypic, protective and nonprotective, and neutralizing and nonneutralizing antibodies. Indeed, all of the challenge viruses in this study elicited both homotypic and lower cross-reactive heterotypic neutralizing antibodies at 28 days. Although it is likely that most of the prechallenge antibodies 4.5 months after vaccination represent serotype-specific protective antibodies rather than heterotypic cross-reactive antibodies, the PRNT assay does not distinguish these 2 types of antibodies. Monkey challenge studies attempt to address the question of whether antibodies induced by TDV will protect humans against disease. In work done by Halstead et al., rhesus monkeys given a single dose of near-wild-type virus seroconverted and were protected against homologous DENV challenge [14]. We evaluated the protection afforded by 4 attenuated viruses in combination. The TDV afforded variable protection against the 4 serotypes. In general, fully protected animals (no viremia) had antibody levels higher than those in unprotected animals. However, although neutralizing antibody as detected by PRNT 50 was necessary, it did not appear to be sufficient for full protection; 3 of 4 vaccinated monkeys developed viremia from challenge, despite having neutralizing antibody. One monkey had a prechallenge titer of 1:119 and still developed viremia from the challenge virus. This finding suggests that immunity to DENV infection is multifactorial and imperfectly predicted by our neutralization test. Our observation in nonhuman primates that the mere presence of neutralizing antibody may not fully correlate with protection is also supported by a recent epidemiologic study [34]. In this prospective study of 2000 Thai schoolchildren, a subgroup of children with DENV-3 DHF had DENV-3 neutralizing antibody before the onset of disease, although the presence of antibody was associated with milder disease. The PRNT assay cannot distinguish homologous protective antibodies from cross-reactive, nonprotective antibodies. Direct evaluation of TDV in a field setting will be required to clearly elucidate the role of antibody in host protection. Viremia is definitive evidence of disseminated viral replication. The TDV provided sterile protection against DENV-2 and at least partial protection against DENV-1, -3, and -4. Even the monkeys with breakthrough viremia tended to have more-abbreviated viremia. The nested PCR assay we used to measure viremia was highly sensitive and able to detect as little as 0, 1, 2, and pfu/ml of DENV-1, -2, -3, and -4, respectively 2log 10 (V. Vassilev, personal communication). No reliable quantitative PCR assay was available to us at the time of this study. A weakness of the nested PCR assay was that it could not distinguish between viable infective virus and neutralized circulating virus. It is possible that, in humans, TDV may at least attenuate, if not totally prevent, disease. Finally, in the 4 vaccinated monkeys with viremia, there was no evidence of antibody enhancement as measured by duration or onset of viremia. On the basis of the results of this study and the results of studies of humans [20], a more balanced immunogenicity will require a more immunogenic DENV-4 component and the TDV to be given with a 2-dose schedule with a longer dose interval. In summary, the results of our study suggest that the TDV conferred protection against all 4 DENV parental challenges in rhesus monkeys. Viral interference among the 4 serotypes of DENV appeared to result in lower immunogenicity for the DENV-3 and -4 components. The imbalance in antibody response can be overcome by revaccination. Clinical studies will be needed to optimize the TDV to achieve a balanced protective immune response. Acknowledgments We recognize the contributions of the many technicians and support personnel who made this study possible in the Department of Virology and Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand, and the Department of Virus Diseases, Walter Reed Army Institute of Medical Sciences, Silver Spring, Maryland. 1664 JID 2006:193 (15 June) Sun et al.

References 1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100 3. 2. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984 1994. Am J Trop Med Hyg 1998; 59:265 71. 3. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30 50. 4. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1987; 18: 392 7. 5. Nimmannitya S. Dengue hemorrhagic fever: diagnosis and management. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Cambridge: CAB International, 1997:133 45. 6. Rothman AL, Green S, Vaughn DW, et al. Dengue hemorrhagic fever. In: Saluzzo JF, Dodet B, eds. Factors in the emergence of arbovirus diseases. Paris: Elsevier, 1997:109 16. 7. Halstead SB, O Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146:201 17. 8. Halstead SB. Antibody-dependent enhancement of infection: a mechanism for indirect virus entry into cells. In: Wimmer E, ed. Cellular receptors for animal viruses. Cold Spring Harbor Laboratory Press, 1994:493 515. 9. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322 30. 10. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213 21. 11. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 1973; 128:7 14. 12. Halstead SB, Palumbo NE. Studies on the immunization of monkeys against dengue: II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 1973; 22:375 81. 13. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 1973; 128:15 22. 14. Halstead SB, Casals J, Shotwell H, Palumbo N. Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections. Am J Trop Med Hyg 1973; 22:365 74. 15. Innis BL, Eckels KH, Kraiselburd D, et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1988; 158:876 80. 16. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralization antibodies. J Immunol 1967; 99: 285 90. 17. Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958; 7:561 73. 18. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy of Sciences Press, 1996. 19. Eckels KH, Dubois DR, Putnak R, et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69:12 6. 20. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69(Suppl 6):24 31. 21. Rosen L, Gubler DJ. The use of mosquitoes to detect and propagate dengue viruses. Am J Trop Med Hyg 1974; 23:1153 60. 22. Jirakanjanakit N, Khin MM, Yoksan S, Bhamarapravati N. The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine. Vaccine 1999; 17:597 601. 23. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992; 30:545 51. 24. Nisalak A, Singharaj P, Halstead SB. Evaluation of sucking mice and tissue culture for recovery of viruses from haemorrhagic fever patients in Thailand. Bull World Health Organ 1966; 35:67. 25. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue virus serotype, virus titers, and antibody response patterns correlate with dengue disease severity. J Infect Dis 2000; 181:2 9. 26. Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761 75. 27. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, liveattenuated tetravalent dengue virus vaccine formulations induce a balanced, broad and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79:5516 28. 28. Sabin AB. Dengue. In: Rivers TM, Horsfall FL Jr, eds. Viral and rickettsial infections of man. 3rd ed. Philadelphia: J. B. Lippincott, 1959: 361 73. 29. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179 88. 30. Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 1974; 23:974 82. 31. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42: 311 28. 32. Kliks SC, Nimmannitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411 9. 33. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444 51. 34. Endy T, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990 1000. DENV Vaccination in Nonhuman Primates JID 2006:193 (15 June) 1665